Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2026 15:40 ET | Source: Tevogen Bio Inc

Letter to Shareholders from CEO Dr. Ryan Saadi

Tevogen CEO outlines potential subsidiary acquisitions targeting $50M+ revenue and positive cash flow to support long-term growth.